Peptide Association
Start Your Consultation
All peptides
MetabolicIn Clinical Trials

Orforglipron

Oral
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Orforglipron is a non-peptide, oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist designed to overcome the need for injectable delivery. It activates the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying.

Mechanism of Action

The therapeutic rationale centers on improving adherence in type 2 diabetes and obesity management by providing once-daily oral dosing as an alternative to injectable GLP-1 receptor agonists.

Research Summary & Key Findings

Phase 2 trials have demonstrated dose-dependent reductions in HbA1c and body weight in adults with type 2 diabetes, with results presented at major diabetes conferences in 2023. Gastrointestinal adverse events were consistent with the GLP-1 agonist class. Phase 3 development is ongoing to establish efficacy and safety in broader patient populations.

Clinical Status

In Clinical Trials

Orforglipron is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Oral

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Start Your Consultation

Get an AI-proposed Orforglipron protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Orforglipron.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.